Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), recently made a significant insider transaction by exercising 10,000 non-qualified stock options and selling the underlying shares in derivative transactions. This move was reported in the SEC Form 4 filing on November 24 and November 25, 2025.
The details of the transaction are as follows:
– Shares sold: 10,000
– Transaction value: Approximately $376,600
– Post-transaction shares: 34,374
– Post-transaction value (direct ownership): Approximately $1.3 million
The transaction involved Mr. Wehrwein exercising his stock options and immediately selling the shares in the open market. This sale represents the largest single event in a series of administrative sales made by Mr. Wehrwein since August 2025, reducing his direct holdings by a total of 20,000 shares.
The transaction price per share was $37.66, slightly higher than the current market price of $36.12 as of November 28, 2025. AtriCure, a company that develops and markets surgical devices for cardiac tissue ablation, has seen a one-year total return of -0.11%, with a net loss of $28.8 million on revenue of $518.3 million.
Despite the recent sale by Mr. Wehrwein, his direct ownership post-transaction represents only 0.07% of outstanding shares. The company’s financial performance has been mixed, with revenue growth but continued losses. AtriCure’s balance sheet shows total assets of $635.4 million compared to total liabilities of $158.9 million.
Investors may want to monitor AtriCure’s performance over the next few quarters before making any investment decisions. The company’s focus on cardiac surgical devices and its established distribution channels position it well in the market, but ongoing losses raise some concerns.
In conclusion, while Mr. Wehrwein’s sale may raise eyebrows, it is essential to consider the broader market context and company performance before making any investment decisions. AtriCure’s financials suggest a cautious approach, with a focus on reducing losses and driving revenue growth in the future.
